

FIGURE 1




Figure 2




Figure 3




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 5C




Figure 5D






Figure 5E




Figure 5F




Figure 6A




Figure 6B




Figure 7A




Figure 7B




Figure 8A




Figure 8B






Fig. 9




Figure 10A




Figure 10B




Figure 10C




Figure 10D




Figure 11






Figure 12

1st dimension: Isoelectric focusing



2nd dimension: SDS PAGE

Figure 13





**Phage Display  
Library Selection**

**scFv Array  
Immunoassay &  
Epitope Mapping**

**Protein-Protein  
Interactions**

***In situ* Protein  
Purification**




FIG. 14





FIG. 15



scFv

Anti-phage Ab

Protein A/G

Target epitope

Drug Candidates




Figure 17




Fig. 18




FIG. 19




FIG. 20




FIG. 21






FIG. 22




Fig. 22A

Fig. 22B

Fig. 22C

Sample	Protein	Area	Intensity
Disease	Int std	1139.044	3.340518
	marker	695.4804	0.580081
Drug treated	Int std	1383.883	3.780178
	marker	71.05119	0.143227

Fig. 22D


Normalized marker peak area (marker/internal std):

Control	0.0
Disease	0.61
Drug treated	0.05

FIG. 23


# Retentate Map™ of Human Urine SELDI ProteinChip™ Array

FIG. 23A



Cancer patient 1  
Cancer patient 2  
Cancer patient 3  
Cancer patient 4  
Normal urine

FIG. 23B



Difference  
map

FIG. 23C



\* markers  
common to  
all patients

FIG. 23D



40,000 60,000 80,000

FIG. 24




FIG. 25




Fig. 25A




Fig. 25B

FIG. 26





FIG. 27



Binding in the absence of free receptor (—)

Binding in the presence of excess free receptor (---)




FIG. 28




Fig. 28A




Fig. 28B




Fig. 28C

5000 10000 15000 20000 25000 30000  
Molecular weight

FIG. 29




Fig. 29A




Fig. 29B




Fig. 29 C

Molecular weight



Figure 30




Figure 31




Figure 32




FIG. 33

Fig. 33A

Intensity

Fig. 33B

